Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0190 UNCHANGED
Streaming Delayed Price Updated: 2:54 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0190
Bid (Size) 0.0150 (4,200)
Ask (Size) 0.0183 (100)
Prev. Close 0.0190
Today's Range 0.0190 - 0.0190
52wk Range 0.0100 - 0.0899
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $5.0 Million Share Repurchase Program
Via ACCESS Newswire

Performance

YTD
+2.2%
+2.2%
1 Month
+11.1%
+11.1%
3 Month
+4.4%
+4.4%
6 Month
-12.0%
-12.0%
1 Year
-61.2%
-61.2%

More News

Read More
News headline image
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
Via ACCESS Newswire
News headline image
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Via ACCESS Newswire
News headline image
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
Via ACCESS Newswire
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Reverse Stock Split
Via ACCESS Newswire

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?
Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.
What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?
Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?
The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market
What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?
The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0190
When was Aspire Biopharma Holdings, Inc. - Warrant last traded?
The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 05/12/26 02:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.